Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients with Malignancies Dependent on Wnt Ligands
Summary
06/28/2018 NOTE: Sites may be enrolling in different cohorts.
The purpose of this phase I trial is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies for whom no effective standard treatment is available.
Biomarker testing to determine if patient is eligible for the trial will be done during pre-screening for the trial; however,prior reports may be acceptable.
General Information
NCT#: NCT01351103
Study ID: CLGK974X2101
Trial Phase: Phase I
Trial Sponsor: Novartis Pharmaceuticals
Therapies Used in This Trial: LGK974, Spartalizumab